Bacteriophage secondary infection

Stephen T Abedon

doi:10.1007/s12250-014-3547-2

February 2015

Stephen T Abedon. Bacteriophage secondary infection[J]. Virologica Sinica, 2015, 30(1): 3-10. doi: 10.1007/s12250-014-3547-2

Citation: Stephen T Abedon. Bacteriophage secondary infection .VIROLOGICA SINICA, 2015, 30(1) : 3-10. http://dx.doi.org/10.1007/s12250-014-3547-2

Bacteriophage secondary infection

Stephen T Abedon ^,

通讯作者： Stephen T Abedon, abedon.1@osu.edu
收稿日期： 2014-11-17
录用日期： 2014-12-29
出版日期： 2015-01-13

Bacteriophage secondary infection

Stephen T Abedon ^,

Department of Microbiology, the Ohio State University, Mansfield, OH 44906, USA

Corresponding author: Stephen T Abedon, abedon.1@osu.edu
Received Date: 17 November 2014
Accepted Date: 29 December 2014
Published Date: 13 January 2015

Abstract

Phages are credited with having been fi rst described in what we now, offi cially, are commemorating as the 100th. anniversary of their discovery. Those one-hundred years of phage history have not been lacking in excitement, controversy, and occasional convolution. One such complication is the concept of secondary infection, which can take on multiple forms with myriad consequences. The terms secondary infection and secondary adsorption, for example, can be used almost synonymously to describe virion interaction with already phage-infected bacteria, and which can result in what are described as superinfection exclusion or superinfection immunity. The phrase secondary infection also may be used equivalently to superinfection or coinfection, with each of these terms borrowed from medical microbiology, and can result in genetic exchange between phages, phage-on-phage parasitism, and various partial reductions in phage productivity that have been termed mutual exclusion, partial exclusion, or the depressor effect. Alternatively, and drawing from epidemiology, secondary infection has been used to describe phage population growth as that can occur during active phage therapy as well as upon phage contamination of industrial ferments. Here primary infections represent initial bacterial population exposure to phages while consequent phage replication can lead to additional, that is, secondary infections of what otherwise are not yet phage-infected bacteria. Here I explore the varying meanings and resultant ambiguity that has been associated with the term secondary infection. I suggest in particular that secondary infection, as distinctly different phenomena, can in multiple ways infl uence the success of phage-mediated biocontrol of bacteria, also known as, phage therapy.

References
1. Abedon S. 2011. Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol. 77:10-40.
2. Abedon ST. 1990. Selection for lysis inhibition in bacteriophage. J Theor Biol. 146:501-511.
  doi: 10.1016/S0022-5193(05)80375-3
3. Abedon ST. 1992. Lysis of lysis inhibited bacteriophage T4-infected cells. J Bacteriol. 174:8073-8080.
  doi: 10.1128/jb.174.24.8073-8080.1992
4. Abedon ST. 1994. Lysis and the interaction between free phages and infected cells. In: The Molecular Biology of Bacteriophage T4. Karam JD, Kutter E, Carlson K, and Guttman B (eds). Washington DC: ASM Press, pp397-405.
5. Abedon ST. 1999. Bacteriophage T4 resistance to lysis-inhibition collapse. Genet Res, 74:1-11.
  doi: 10.1017/S0016672399003833
6. Abedon ST. 2008. Phage population growth: constraints, games, adaptation. In: Bacteriophage Ecology. Abedon ST (ed). Cambridge: Cambridge University Press, pp64-93.
7. Abedon ST. 2009a. Bacteriophage intraspecific cooperation and defection. In: Contemporary Trends in Bacteriophage Research.
8. Adams HT (ed). Hauppauge: Nova Science Publishers, pp191-215.
9. Abedon ST. 2009b. Disambiguating bacteriophage pseudolysogeny: an historical analysis of lysogeny, pseudolysogeny, and the phage carrier state. In: Contemporary Trends in Bacteriophage Research. Adams HT (ed). Hauppauge: Nova Science Publishers, pp285-307.
10. Abedon ST. 2009c. Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis, 6:807-815.
  doi: 10.1089/fpd.2008.0242
11. Abedon ST. 2011a. Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques. Hauppauge: Nova Science Publishers.
12. Abedon ST. 2011b. Lysis from without. Bacteriophage. 1: 46-49.
13. Abedon ST. 2012a. Phage therapy best practices. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (eds). Wallingford: CABI Press, pp256-272.
14. Abedon ST. 2012b. Spatial vulnerability: bacterial arrangements, microcolonies, and biofilms as responses to low rather than high phage densities. Viruses. 4:663-687.
  doi: 10.3390/v4050663
15. Abedon ST. 2012c. Thinking about microcolonies as phage targets. Bacteriophage. 2:200-204.
  doi: 10.4161/bact.22444
16. Abedon ST. 2014. Bacteriophages as drugs: the pharmacology of phage therapy. In: Phage Therapy: Current Research and Applications. Borysowski J, Miedzybrodzki R, and Górski A (eds). Norfolk: Caister Academic Press, pp69-100.
17. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections. Bacteriophage. 1:66-85.
  doi: 10.4161/bact.1.2.15845
18. Abedon ST, Thomas-Abedon C. 2010. Phage therapy pharmacology. Curr Pharm Biotechnol. 11:28-47.
  doi: 10.2174/138920110790725410
19. Adams MH. 1959. Bacteriophages. New York: InterScience.
20. Barron BA, Fischetti VA, Zabriskie JB. 1970. Studies of the bacteriophage kinetics of multicellular systems: a statistical model for the estimation of burst size per cell in streptococci. J Appl Bacteriol. 33:436-442.
  doi: 10.1111/jam.1970.33.issue-2
21. Benzer S, Hudson W, Weidel W, Delbruck M, Stent GS, Weigle J J, Dulbecco R, Watson JD, Wollman EL. 1950. A syllabus on procedures, facts, and interpretations in phage. Viruses 1950. Delbruck M (ed). Pasadena: California Institute of Technology, pp100-147.
22. Berngruber TW, Weissing FJ, Gandon S. 2010. Superinfection inhibition and the evolution of viral latency. J Virol, 84:10200-10208.
  doi: 10.1128/JVI.00865-10
23. Bigwood T, Hudson JA, Billington C. 2009. Influence of host and bacteriophage concentrations on the inactivation of foodborne pathogenic bacteria by two phages. FEMS Microbiol Lett, 291:59-64.
  doi: 10.1111/fml.2009.291.issue-1
24. Bull JJ, Regoes RR. 2006. Pharmacodynamics of non-replicating viruses, bacteriocins and lysins. Proc R Soc Lond B Biol Sci, 273:2703-2712.
  doi: 10.1098/rspb.2006.3640
25. Chan BK, Abedon ST. 2012. Phage therapy pharmacology: phage cocktails. Adv Appl Microbiol, 78:1-23.
  doi: 10.1016/B978-0-12-394805-2.00001-4
26. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol, 8:769-783.
  doi: 10.2217/fmb.13.47
27. Davis BM, Kimsey HH, Chang W, Waldor MK. 1999. The Vibrio cholerae O139 Calcutta bacteriophage CTXφ is infectious and encodes a novel repressor. J Bacteriol, 181:6779-6787.
28. Doermann AH. 1948. Lysis and lysis inhibition with Escherichia coli bacteriophage. J Bacteriol, 55:257-275.
29. Espeland EM, Lipp EK, Huq A, Colwell RR. 2004. Polylysogeny and prophage induction by secondary infection in Vibrio cholerae. Environ Microbiol, 6:760-763.
  doi: 10.1111/emi.2004.6.issue-7
30. Fogg PC, Allison HE, Saunders JR, McCarthy AJ. 2010. Bacteriophage lambda: a paradigm revisited. J Virol, 84:6876-6879.
  doi: 10.1128/JVI.02177-09
31. Fogg PCM, Gossage SM, Smith DL, Saunders JR, McCarthy AJ, Allison HE. 2007. Identification of multiple integration sites for Stx-phage φ24B in the Escherichia coli genome, description of a novel integrase and evidence for a functional anti-repressor. Microbiology. 153:4098-4110.
  doi: 10.1099/mic.0.2007/011205-0
32. French RC, Graham AF, Lesley SM, van Rooyen CE. 1952. The contribution of phosphorus from T2r⁺ bacteriophage to progeny. J Bacteriol. 64:597-607.
33. Fukuda E, Kaminska KH, Bujnicki JM, Kobayashi I. 2008. Cell death upon epigenetic genome methylation: a novel function of methyl-specific deoxyribonucleases. Genome Biol. 9:R163.
  doi: 10.1186/gb-2008-9-11-r163
34. Golshahi L, Seed KD, Dennis JJ, Finlay WH. 2008. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv, 21:351-360.
  doi: 10.1089/jamp.2008.0701
35. Hatfull GF, Hendrix RW. 2011. Bacteriophages and their genomes. Curr Opin Virol, 1:298-303.
  doi: 10.1016/j.coviro.2011.06.009
36. Hendrix RW. 2008. Phage evolution. In: Bacteriophage Ecology. Abedon ST (ed). Cambridge: Cambridge University Press, pp177-194.
37. Hendrix RW, Smith MCM, Burns RN, Ford ME, Hatfull GF. 1999. Evolutionary relationships among diverse bacteriophages and prophages: All the world's a phage. Proc Natl Acad Sci USA. 96:2192-2197.
  doi: 10.1073/pnas.96.5.2192
38. Hudson JA, Billington C, Carey-Smith G, Greening G. 2005. Bacteriophages as biocontrol agents in food. J Food Prot, 68:426-437.
  doi: 10.4315/0362-028X-68.2.426
39. Hughes KA, Sutherland IW, Jones MV. 1998. Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Microbiology. 144:3039-3047.
  doi: 10.1099/00221287-144-11-3039
40. Hyman P, Abedon ST. 2010. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol, 70:217-248.
  doi: 10.1016/S0065-2164(10)70007-1
41. Hyman P, Abedon ST. 2012. Smaller fleas: viruses of microorganisms. Scientifica. 2012:734023.
42. Iyer VN, James AP. 1978. Single-cell studies on the carrier state of bacteriophage IKe, a virus specific for conjugative plasmids of the N incompatibility and conjugative group. Can J Microbiol, 24:1595-1601.
  doi: 10.1139/m78-255
43. Mann NH. 2003. Phages of the marine cyanobacterial picophytoplankton. FEMS Microbiol Rev, 27:17-34.
  doi: 10.1016/S0168-6445(03)00016-0
44. May RM, Anderson RM. 1983. Parasite-host coevolution. In: Coevolution. Futuyma DJ, Slatkin M (eds). Sunderland: Sinauer Associates, pp186-206.
45. Moussa SH, Kuznetsov V, Tran TA, Sacchettini JC, Young R. 2012. Protein determinants of phage T4 lysis inhibition. Protein Sci, 21:571-582.
  doi: 10.1002/pro.2042
46. Moussa SH, Lawler JL, Young R. 2014. Genetic dissection of T4 lysis. J Bacteriol, 196:2201-2209.
  doi: 10.1128/JB.01548-14
47. Payne RJH, Jansen VAA. 2001. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol, 208:37-48.
  doi: 10.1006/jtbi.2000.2198
48. Payne RJH, Jansen VAA. 2003. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet, 42:315-325.
  doi: 10.2165/00003088-200342040-00002
49. Payne RJH, Phil D, Jansen VAA. 2000. Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther, 68:225-230.
  doi: 10.1067/mcp.2000.109520
50. Pratt JH. 1899. Secondary infection of the skin and subcutaneous tissues by the bacillus typhosus. J Boston Soc Med Sci, 3:170-173.
51. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. 2011. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharamcol, 63:1253-1264.
  doi: 10.1111/j.2042-7158.2011.01324.x
52. Sanders ME. 1987. Bacteriophages of industrial importance. In: Phage Ecology. Goyal SM, Gerba GP, Bitton G (eds). New York: John Wiley & Sons, pp211-244.
53. Slavcev RA, Hayes S. 2002. Rex-centric mutualism. J Bacteriol, 184:857-858.
  doi: 10.1128/JB.184.3.857-858.2002
54. Smith DL, Rooks DJ, Fogg PC, Darby AC, Thomson NR, McCarthy AJ, Allison HE. 2012. Comparative genomics of Shiga toxin encoding bacteriophages. BMC Genomics, 13:311.
  doi: 10.1186/1471-2164-13-311
55. Stent GS. 1963. Molecular biology of bacterial viruses. San Francisco: WH Freeman and Co.
56. Sturino JM, Klaenhammer TR. 2006. Engineered bacteriophage-defence systems in bioprocessing. Nat Rev Microbiol, 4:395-404.
  doi: 10.1038/nrmicro1393
57. Tran TA, Struck DK, Young R. 2005. Periplasmic domains define holin-antiholin interactions in T4 lysis inhibition. J Bacteriol, 187:6631-6640.
  doi: 10.1128/JB.187.19.6631-6640.2005
58. Tran TA, Struck DK, Young R. 2007. The T4 RI antiholin has an N-terminal signal anchor release domain that targets it for degradation by DegP. J Bacteriol, 189:7618-7625.
  doi: 10.1128/JB.00854-07
59. Turner PE, Duffy S. 2008. Evolutionary ecology of multi-phage infections. In: Bacteriophage Ecology. Abedon ST (ed). Cambridge: Cambridge University Press, pp195-216.
60. Wei W, Krone SM. 2005. Spatial invasion by a mutant pathogen. J Theor Biol, 236:335-348.
  doi: 10.1016/j.jtbi.2005.03.016
61. Weinfeld H, Paigen K. 1964. Evidence for a new intermediate state of the viral chromosome during cooperative infection by host-modified lambda phage. Virology, 24:71-83.
  doi: 10.1016/0042-6822(64)90149-7
62. Werner ER, Christensen JR. 1969. Infection by bacteriophage P1 and development of host-controlled restriction and modification and of lysogenic immunity. J Virol, 3:363-368.
63. Yamada T, Kawasaki T, Nagata S, Fujiwara A, Usami S, Fujie M. 2007. New bacteriophages that infect the phytopathogen Ralstonia solanacearum. Microbiology.153:2630-2639.
  doi: 10.1099/mic.0.2006/001453-0
Proportional views